Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare p
Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhib
Featuring a slide presentation and related discussion from Dr Floor J Backes, including the following topics: Recent updates from ASCO 2023 in the management of ovarian cancer (0:00) Recent updates from ASCO 2023 in the management of endometri
Featuring a discussion on recent updates in the management of gynecologic cancers from the ASCO 2023 Annual Meeting with Dr Floor Backes, moderated by Dr Neil Love.
Featuring perspectives from Dr Floor J Backes, including the following topics: Available data with and clinical investigator perspectives on trastuzumab deruxtecan for the management of gynecologic cancers (0:00) Patient-specific factors guidi